Results 21 to 30 of about 18,136 (239)

F-18-FDG and C-11-choline positron emission tomography in human esophago-gastric cancer : prediction of response to therapy [PDF]

open access: yes, 2010
Peer reviewedPublisher ...
Hammonds, Solveig   +8 more
core   +1 more source

Esophageal and Esophagogastric Junction Cancers [PDF]

open access: yesJournal of the National Comprehensive Cancer Network, 2011
Overview Upper gastrointestinal tract cancers originating in the esophagus, esophagogastric junction (EGJ), and stomach constitute a major health problem around the world. An estimated 37,640 new cases of and 25,070 deaths from upper gastrointestinal cancers occurred in the United States in 2010.1 A dramatic shift in the location of upper ...
Jaffer A, Ajani   +28 more
openaire   +2 more sources

Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the International BEACON Consortium [PDF]

open access: yes, 2010
BackgroundPrevious studies that showed an association between smoking and adenocarcinomas of the esophagus and esophagogastric junction were limited in their ability to assess differences by tumor site, sex, dose–response, and duration of cigarette ...
Abnet, C.C.   +21 more
core   +1 more source

Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma [PDF]

open access: yes, 2013
This study aimed at determining the recommended dose of the mammalian target of rapamycin inhibitor everolimus in combination with mitomycin C (MMC) in patients with previously treated metastatic esophagogastric cancer.
Atmaca, Akin   +5 more
core   +1 more source

Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT

open access: yesBMC Cancer, 2019
Background The prognosis of patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma is still dismal. There are no standard treatment strategies for these patients.
Xiaowen Liu   +23 more
doaj   +1 more source

Evaluation of the incidence of splenic hilar lymph node metastasis in patients operated on for esophagogastric junction cancer

open access: yesNowotwory, 2023
INTRODUCTION: The purpose of this study is to evaluate the effect of esophagogastric junction cancer (EGJC) staging on the risk of splenic hilar lymph node involvement. MATERIAL AND METHODS: 312 patients with EGJC after R0 surgery were analyzed; 118 (38%)
Tomasz Olesiński   +4 more
doaj   +1 more source

Diagnostic performance in T staging for patients with esophagogastric junction cancer using high-resolution MRI: a comparison with conventional MRI at 3 tesla

open access: yesCancer Imaging, 2019
Background To investigate and compare the diagnostic performance in T staging for patients with esophagogastric junction cancer using high-resolution magnetic resonance imaging (HR MRI), as compared with conventional MRI at 3 Tesla.
Yuan Yuan   +13 more
doaj   +1 more source

Treatment of esophageal achalasia in children: Today and tomorrow [PDF]

open access: yes, 2015
Esophageal achalasia (EA) is a rare esophageal motility disorder in children. Laparoscopic Heller myotomy (LHM) represents the treatment of choice in young patients. Peroral endoscopic myotomy (POEM) is becoming an alternative to LHM.
Caldaro, T   +11 more
core   +1 more source

Morphology of the Esophageal Hiatus: Is It Different in 3 Types of Hiatus Hernias? [PDF]

open access: yes, 2020
Background/aimsThe esophageal hiatus is formed by the right crus of the diaphragm in the majority of subjects. Contraction of the hiatus exerts a sphincter-like action on the lower esophageal sphincter (LES). The aim is to study the hiatal anatomy (using
Ghahremani, Gary   +5 more
core   +1 more source

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction

open access: yesWorld Journal of Surgical Oncology, 2012
Background The epidermal growth factor receptor (EGFR) inhibitor, gefitinib, has been reported to successfully treat advanced non-small cell lung cancer patients with genetic mutations in EGFR.
Wang Wen-Ping   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy